Archive for October, 2005
Breast Cancer: Further Support for Trastuzumab from Combined Analysis
Edward Romond
Edward Romond, University of Kentucky, Lexington
More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
Audio Journal of Cardiovascular Medicine 11.3, October 2005
Reporting from:
European Society of Cardiology Congress September 3-7, 2005, Stockholm
In this edition:
The RITA-3 trial - focussing on how to manage patients with acute coronary syndromes - reported 5-year data at this year’s ESC Congress. Keith Fox talked about new evidence that strengthens the case for aggressive management of patients.
The conference also heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578. Jean Fajadet from Toulouse discussed the ENDEAVOR-2 study.
A future option for treating in-stent restenosis by coating a balloon with an anti-proliferative drug and inflating it inside the newly-occluded stent was discussed at the ESC Congress by Bruno Scheller who presented the first study of such a device in humans.
In the treatment of acute myocardial infarction, the 24-country ASSENT-4 study seems to show an overall increase of risk if you use thrombolysis before primary PCI. Frans Van de Werf gave the 30 day analysis. Kim Fox comments.
…
Phil Edwards, London School of Hyugiene and Tropical Medicine
